We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00268203
First Posted: December 22, 2005
Last Update Posted: January 9, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
GlaxoSmithKline
Results First Submitted: October 10, 2013  
Study Type: Interventional
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Iodine I 131 Tositumomab Therapeutic Regimen

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
NHL=Non-Hodgkin's Lymphoma.

Reporting Groups
  Description
Tositumomab and Iodine I-131 Tositumomab Participants were treated with a saturated solution of potassium iodide (KI), Lugol’s solution, or KI tablets starting at least 24 hours prior to the first infusion of Iodine I-131 Tositumomab (TST) and continuing for 14 days following the last infusion of Iodine I-131 TST. Participants received treatment in two phases. The dosimetric dose was administered in Phase 1 as 450 milligrams (mg) of TST infused over 1 hour (preceded by the administration of oral acetaminophen and an antihistamine), followed by 5 millicurie (mCi) of Iodine I-131 TST infused over 20 minutes (min), followed by a 10-min normal saline flush. The therapeutic dose, administered 7–14 days after the dosimetric dose, was administered as 450 mg of TST infused over 1 hour (preceded by the administration of oral acetaminophen and an antihistamine), followed by the appropriate activity (mCi) of Iodine I-131 TST infused over 20 min, followed by a 10-min normal saline flush.

Participant Flow:   Overall Study
    Tositumomab and Iodine I-131 Tositumomab
STARTED   765 
Completed 2 Years of Follow-up   62 
COMPLETED   118 [1] 
NOT COMPLETED   647 
Lost to Follow-up                92 
Withdrawal by Subject                9 
Received Other NHL Therapy                7 
Progressive Disease                359 
Death                84 
Reason Not Specified                34 
Completed 2 Years of Follow-up                62 
[1] These participants completed 10 years of follow-up.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Tositumomab and Iodine I-131 Tositumomab Participants were treated with a saturated solution of potassium iodide (KI), Lugol’s solution, or KI tablets starting at least 24 hours prior to the first infusion of Iodine I-131 Tositumomab (TST) and continuing for 14 days following the last infusion of Iodine I-131 TST. Participants received treatment in two phases. The dosimetric dose was administered in Phase 1 as 450 milligrams (mg) of TST infused over 1 hour (preceded by the administration of oral acetaminophen and an antihistamine), followed by 5 millicurie (mCi) of Iodine I-131 TST infused over 20 minutes (min), followed by a 10-min normal saline flush. The therapeutic dose, administered 7–14 days after the dosimetric dose, was administered as 450 mg of TST infused over 1 hour (preceded by the administration of oral acetaminophen and an antihistamine), followed by the appropriate activity (mCi) of Iodine I-131 TST infused over 20 min, followed by a 10-min normal saline flush.

Baseline Measures
   Tositumomab and Iodine I-131 Tositumomab 
Overall Participants Analyzed 
[Units: Participants]
 765 
Age 
[Units: Years]
Mean (Standard Deviation)
 58.8  (11.5) 
Gender 
[Units: Participants]
Count of Participants
 
Female      354  46.3% 
Male      411  53.7% 
Race/Ethnicity, Customized [1] 
[Units: Participants]
 
White   711 
Hispanic   19 
Asian   7 
Black   20 
Native American   1 
Portuguese   1 
Middle Eastern   1 
Iranian   1 
Indian   2 
Arab   1 
Peruvian   1 
[1] Race data were not collected; ethnicity data were collected and are presented instead.


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Unconfirmed Response (Complete Response or Partial Response) and Unconfirmed Complete Response   [ Time Frame: From randomization until the first documented complete response or partial response (up to 161 months) ]

2.  Primary:   Number of Participants With Confirmed Response (Complete Response or Partial Response) and Confirmed Complete Response   [ Time Frame: From randomization until the first documented complete response or partial response (up to 161 months) ]

3.  Primary:   Duration of Response for Participants With Unconfirmed Response (CR+PR)   [ Time Frame: From the time of the first documented response (CR or PR) until disease progression (up to 161 months) ]

4.  Primary:   Duration of Response for Participants With Confirmed Response (CR+PR)   [ Time Frame: From the time of the first documented response (CR or PR) until disease progression (up to 161 months) ]

5.  Primary:   Duration of Response (DOR) in Unconfirmed Complete Responders   [ Time Frame: From the time of the first documented unconfirmed CR until PD (up to 161 months) ]

6.  Primary:   Duration of Response (DOR) in Confirmed Complete Responders   [ Time Frame: From the time of the first documented CR until PD (up to 161 months) ]

7.  Primary:   Time to Progression or Death   [ Time Frame: From the treatment start date to the first documented incidence of disease progression (PD) or death (up to 161 months) ]

8.  Secondary:   Time to Treatment Failure   [ Time Frame: From the dosimetric dose to the first occurrence of the following: treatment withdrawal, decision to seek additional therapy, study removal, disease progression, receipt of alternative therapy, or death (up to 161 months) ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: GSK Response Center
Organization: GlaxoSmithKline
phone: 866-435-7343



Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00268203     History of Changes
Other Study ID Numbers: BEX104545
First Submitted: December 20, 2005
First Posted: December 22, 2005
Results First Submitted: October 10, 2013
Results First Posted: December 9, 2013
Last Update Posted: January 9, 2017